Recent Quotes (30 days)

You have no recent quotes
chg | %

Ceapro Inc.  

(Public, CVE:CZO)   Watch this stock  
Find more results for CZO
0.000 (0.00%)
Apr 17 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.12 - 0.12
52 week 0.03 - 0.14
Open 0.12
Vol / Avg. 18,055.00/28,940.00
Mkt cap 7.23M
P/E 173.91
Div/yield     -
EPS 0.00
Shares 60.28M
Beta 1.09
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 6.17% -10.42%
Operating margin 9.93% -9.96%
EBITD margin - -2.11%
Return on average assets 14.75% -13.36%
Return on average equity 181.55% -202.65%
Employees 12 -
CDP Score - -


Suite 4174 Enterprise Square 10230 Jasper Avenue NW
+1-780-4214555 (Phone)
+1-780-4211320 (Fax)

Website links


Ceapro Inc. (Ceapro) is a biotechnology company engaged in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. The Company´┐Żs primary business activities relate to the marketing and development of various health and wellness products and technology relating to plant extracts. Its product pipeline include Oat Products and Botanical Products. Oat Products include CP Oat Avenanthramides, CP Oat Beta Glucan and Oat Oil. The oat-derived compounds avenanthramides and beta glucan constitute its core product base. Its Botanical Products include CP Sweet Blue Lupin. Ceapro operates in one industry segment, which is the active ingredient product technology industry. The majority of the revenue is derived from sales in North America.

Officers and directors

Edward A. Taylor Independent Chairman of the Board
Age: 67
Gilles R. Gagnon President, Chief Executive Officer, Director
Age: 59
Branko Jankovic Chief Financial Officer, Corporate Secretary
Donald J. Oborowsky Independent Director
Glenn Rourke Independent Director
John Zupancic Independent Director